Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Opthea's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OPT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: OPT's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: OPT underperformed the Australian Biotechs industry which returned -9.4% over the past year.
Return vs Market: OPT underperformed the Australian Market which returned 37.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Opthea's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StWhat Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?
2 months ago | Simply Wall StWe Think Opthea (ASX:OPT) Can Afford To Drive Business Growth
4 months ago | Simply Wall StWhat Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?
Is Opthea undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: OPT (A$1.39) is trading above our estimate of fair value (A$0.66)
Significantly Below Fair Value: OPT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OPT is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.
PE vs Market: OPT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OPT is good value based on its PB Ratio (2.4x) compared to the AU Biotechs industry average (4.8x).
How is Opthea forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OPT's revenue (105.4% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: OPT's revenue (105.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OPT is forecast to be unprofitable in 3 years.
How has Opthea performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPT is currently unprofitable.
Growing Profit Margin: OPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPT is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.
Accelerating Growth: Unable to compare OPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: OPT has a negative Return on Equity (-22.21%), as it is currently unprofitable.
How is Opthea's financial position?
Financial Position Analysis
Short Term Liabilities: OPT's short term assets (A$213.0M) exceed its short term liabilities (A$15.5M).
Long Term Liabilities: OPT's short term assets (A$213.0M) exceed its long term liabilities (A$111.5K).
Debt to Equity History and Analysis
Debt Level: OPT is debt free.
Reducing Debt: OPT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: OPT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 31.6% each year.
What is Opthea current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Megan Baldwin (45 yo)
Dr. Megan Baldwin, PhD, MAICD, serves as Non-Executive Director at Invex Therapeutics Ltd since February 16, 2021. Dr. Baldwin has been the Chief Executive Officer and Managing Director at Opthea Limited (...
CEO Compensation Analysis
Compensation vs Market: Megan's total compensation ($USD654.70K) is about average for companies of similar size in the Australian market ($USD712.72K).
Compensation vs Earnings: Megan's compensation has been consistent with company performance over the past year.
Experienced Management: OPT's management team is seasoned and experienced (9.7 years average tenure).
Experienced Board: OPT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.2%.
Opthea Limited's company bio, employee growth, exchange listings and data sources
- Name: Opthea Limited
- Ticker: OPT
- Exchange: ASX
- Founded: 1984
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$486.720m
- Shares outstanding: 347.66m
- Website: https://www.opthea.com
- Opthea Limited
- 650 Chapel Street
- Suite 0403
- South Yarra
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 08:59|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.